Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery

Keyphrases

• Vomiting 100%
• Postoperative Nausea 100%
• Bariatric Surgery 100%
• Aprepitant 100%
• Morbidly Obese Patients 100%
• Prophylactic Efficacy 100%
• Nausea 42%
• Ondansetron 28%
• Laparoscopic Bariatric Surgery 28%
• Odds Ratio 14%
• Placebo 14%
• Body Mass Index 14%
• No Significant Difference 14%
• Number of Patients 14%
• Between-group 14%
• Timing of Surgery 14%
• Cumulative Incidence 14%
• Institutional Review Board 14%
• Evenly Distributed 14%
• Double-blind Placebo-controlled Trial 14%
• P-15 14%
• Type of Surgery 14%
• Patient Dissatisfaction 14%
• Kaplan-Meier Plot 14%
• Neurokinin-1 14%
• Surgical Anastomosis 14%
• Random Division 14%
• Retching 14%
• Prophylactic Antiemetics 14%

Medicine and Dentistry

• Bariatric Surgery 100%
• Postoperative Nausea and Vomiting 100%
• Aprepitant 100%
• Nausea 40%
• Placebo 40%
• Ondansetron 40%
• Operation Duration 20%
• Body Mass Index 20%
• Surgical Anastomosis 20%
• Division 20%
• Cumulative Incidence 20%
• Nausea and Vomiting 20%
• Antiemetic 20%
• Retching 20%
• Postoperative Vomiting 20%
• Substance P 20%
• Odds Ratio 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Aprepitant 100%
• Postoperative Nausea and Vomiting 100%
• Placebo 40%
• Nausea 40%
• Zofran 40%
• Postoperative Vomiting 20%
• Nausea and Vomiting 20%
• Antiemetic Agent 20%
• Tablet 20%
• Retching 20%
• Substance P 20%